119 related articles for article (PubMed ID: 21320484)
21. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
22. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
Chang H; Jeung HC; Jung JJ; Kim TS; Rha SY; Chung HC
Breast Cancer Res Treat; 2011 Jan; 125(1):55-63. PubMed ID: 20224928
[TBL] [Abstract][Full Text] [Related]
23. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines.
Kars MD; Işeri OD; Gunduz U; Molnar J
Chemotherapy; 2008; 54(3):194-200. PubMed ID: 18560226
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
25. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
Duan Z; Feller AJ; Penson RT; Chabner BA; Seiden MV
Clin Cancer Res; 1999 Nov; 5(11):3445-53. PubMed ID: 10589757
[TBL] [Abstract][Full Text] [Related]
26. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production.
Shi Z; Yang WM; Chen LP; Yang DH; Zhou Q; Zhu J; Chen JJ; Huang RC; Chen ZS; Huang RP
Breast Cancer Res Treat; 2012 Oct; 135(3):737-47. PubMed ID: 22923236
[TBL] [Abstract][Full Text] [Related]
27. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
29. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
[TBL] [Abstract][Full Text] [Related]
30. Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer.
Labbozzetta M; Notarbartolo M; Poma P; Maurici A; Inguglia L; Marchetti P; Rizzi M; Baruchello R; Simoni D; D'Alessandro N
Ann N Y Acad Sci; 2009 Feb; 1155():278-83. PubMed ID: 19250217
[TBL] [Abstract][Full Text] [Related]
31. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
32. The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis.
Poma P; Notarbartolo M; Labbozzetta M; Maurici A; Carina V; Alaimo A; Rizzi M; Simoni D; D'Alessandro N
Int J Mol Med; 2007 Sep; 20(3):329-35. PubMed ID: 17671737
[TBL] [Abstract][Full Text] [Related]
33. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
34. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin.
Lukyanova NY; Rusetskya NV; Tregubova NA; Chekhun VF
Exp Oncol; 2009 Jun; 31(2):87-91. PubMed ID: 19550397
[TBL] [Abstract][Full Text] [Related]
35. 3-D tumor model for in vitro evaluation of anticancer drugs.
Horning JL; Sahoo SK; Vijayaraghavalu S; Dimitrijevic S; Vasir JK; Jain TK; Panda AK; Labhasetwar V
Mol Pharm; 2008; 5(5):849-62. PubMed ID: 18680382
[TBL] [Abstract][Full Text] [Related]
36. Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines.
Januchowski R; Wojtowicz K; Andrzejewska M; Zabel M
Biomed Pharmacother; 2014 Feb; 68(1):111-7. PubMed ID: 24140176
[TBL] [Abstract][Full Text] [Related]
37. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model.
Watson MB; Lind MJ; Smith L; Drew PJ; Cawkwell L
Acta Oncol; 2007; 46(5):651-8. PubMed ID: 17562441
[TBL] [Abstract][Full Text] [Related]
38. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
Pennanen PT; Sarvilinna NS; Ylikomi TJ
Anticancer Drugs; 2009 Jan; 20(1):51-8. PubMed ID: 19343000
[TBL] [Abstract][Full Text] [Related]
39. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery.
Yao HJ; Ju RJ; Wang XX; Zhang Y; Li RJ; Yu Y; Zhang L; Lu WL
Biomaterials; 2011 Apr; 32(12):3285-302. PubMed ID: 21306774
[TBL] [Abstract][Full Text] [Related]
40. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells.
Mallory JC; Crudden G; Oliva A; Saunders C; Stromberg A; Craven RJ
Mol Pharmacol; 2005 Dec; 68(6):1747-56. PubMed ID: 16150928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
